

**Results** The cell population included large consistency of positive cells (A) which were analyzed in their vitality using the PC5-conjugated-7-AAD viability marker. Almost the full population, namely 95.7% of Ddx4<sup>+</sup> cells were found viable among a minority equal to 4.3% of dead cells (B-C), suggesting that the fragments cryopreservation in liquid nitrogen is almost indolent on the OSC viability.

**Conclusion** The consistency of OSC population from a single cryopreserved ovarian cortex after thawing suggest that this population is apparently resistant to the temperature stress for freezing and thawing, thus reinforcing interest for stemness studies in treatment of female CTRI.

**2022-VA-596-ESGO LAPAROSCOPIC VAGINAL RADICAL TRACHELECTOMY IN THE POST LACC ERA: STEP BY STEP SURGICAL PROCEDURE**

<sup>1,2</sup>Benedetta Guani, <sup>3</sup>Vincent Balaya, <sup>4</sup>Fabrice Lecuru, <sup>1</sup>Patrice Matehvet. <sup>1</sup>CHUV, Lausanne, Switzerland; <sup>2</sup>HFR, Fribourg, Switzerland; <sup>3</sup>Hopital Foch, suresnes, France; <sup>4</sup>Hopital Curie, Paris, France

10.1136/ijgc-2022-ESGO.369

**Introduction/Background** Therapeutic management of early stage cervical cancer is mainly based on surgery. Radical trachelectomy is a strategy to preserve the fertility of young patients with cervical cancer. In the ESGO and NCCN Guidelines, Radical Trachelectomy type B is indicated in case of cervical cancer stage 1B1. The prospective CONCERTV study shows the safety of the simple conisation in early-stage cervical cancer <2 cm in case of stromal invasion <10 mm and no lymph vascular space invasion. Actually the indication to the radical trachelectomy remains:-Cervical cancer <2 cm-FIGO stage not more 1B1-Negative lymph node-Positive LVSI

The oncological safety of the minimally invasive approach has recently questioned by the international randomized LACC trial. This result have therefore renewed interest in the vaginal approach, associated to lymph node staging by laparoscopy.

**Methodology** We described the indication and the procedure in a video.

**Results** In this video we described the radical trachelectomy by the laparoscopic vaginal approach in 10 steps.



Abstract 2022-VA-596-ESGO Figure 1


**Conclusion** This technique is a safe oncological procedure in the post-LACC era.

**2022-RA-598-ESGO PROGNOSTIC FACTORS FOR ADVERSE OBSTETRIC OUTCOMES IN PREGNANT CANCER PATIENTS AN UPDATE ON 2174 CASES REGISTERED IN THE INCIP REGISTRY**


<sup>1</sup>Charlotte Maggen, <sup>2</sup>Joosje Heimovaara, <sup>3</sup>Kristel van Calsteren, <sup>4</sup>Elyce Cardonick, <sup>5</sup>Annouschka Laenen, <sup>6</sup>Roman G Shmakov, <sup>7</sup>Vera Wolters, <sup>8</sup>Mina Mhallem Gziri, <sup>7</sup>Christianne Lok, <sup>6</sup>Evgeniya Polushkina, <sup>2</sup>Jeroen Blommaert, <sup>9</sup>Michael Halaska, <sup>10</sup>Robert Fruscio, <sup>11</sup>Alvaro Cabrera-García, <sup>12</sup>Ingrid A Boere, <sup>13</sup>Ingrid A Boere, <sup>14</sup>Petronella Ottevanger, <sup>15</sup>Giovanna Scarfone, <sup>16</sup>Jorine de Haan, <sup>3</sup>Frédéric Amant. <sup>1</sup>Obstetrics and perinatal medicine, UZ Brussels, Jette, Belgium; <sup>2</sup>KU Leuven, Leuven, Belgium; <sup>3</sup>University Hospitals of Leuven, Leuven, Belgium; <sup>4</sup>Department of Obstetrics and Gynecology, Cooper, University Health Care, Camden, NJ, USA, Camden, NJ; <sup>5</sup>Statistics, KU Leuven, Leuven, Belgium; <sup>6</sup>National Medical Research Centre for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov of the Ministry of Healthcare of Russian Federation, Moscow, Russia, Moscow, Russian Federation; <sup>7</sup>Department of Gynecology, Antoni van Leeuwenhoek – Netherlands Cancer Institute, Amsterdam, The Netherlands, Amsterdam, Netherlands; <sup>8</sup>Department of Obstetrics, Cliniques Universitaires St Luc, UCL, Sint-Lambrechts-Woluwe, Belgium, Sint-Lambrechts-Woluwe, Belgium; <sup>9</sup>Faculty Hospital Kralovske, Vinohrady and 3rd Medical Faculty, Charles University, Prague, Czech Republic, Prague, Czech Republic; <sup>10</sup>Clinic of Obstetrics and Gynecology, University of Milan – Bicocca, San Gerardo Hospital, Monza, Italy, Milan, Italy; <sup>11</sup>Hospital Regional de Alta Especialidad de Ixtapaluca (HRAEI) 'Reference clinic for hemato-oncological diseases during pregnancy CREHER' Estado de México, México, Mexico, Mexico; <sup>12</sup>Department of Medical Oncology, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands., Rotterdam, Netherlands; <sup>13</sup>Department of Obstetrics and Gynecology, University of Turin, Città della Salute e della Scienza, Sant'Anna Hospital, via Ventimiglia 1, 10126, Turin, Italy., Turin, Italy; <sup>14</sup>Department of Medical Oncology, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands., Nijmegen, Netherlands; <sup>15</sup>Gynecological Oncology Unit, Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico, Ca' Granda Ospedale Maggiore Policlinico Milan, Milan, Italy., Milan, Italy; <sup>16</sup>Department of Obstetrics and Gynecology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Amsterdam, Netherlands

10.1136/ijgc-2022-ESGO.370

**Introduction/Background** Following the increasing evidence on fetal safety, over time more pregnant women are receiving cancer treatment, including chemotherapy, in order to safeguard maternal prognosis. To evaluate current clinical practice obstetric and neonatal outcomes of women registered by the International Network on Cancer, Infertility and Pregnancy (INCIP) were assessed.



Abstract 2022-RA-598-ESGO Figure 1 Distribution of cancer types and cancer stages at diagnosis by cancer type (n=2174)



**Abstract 2022-RA-598-ESGO Figure 2** Evolution in oncological management (A), obstetric outcome (B) and obstetric and neonatal complications © in pregnant cancer patients over 25 years (1996–2021)

**Methodology** Women with a primary or recurrent invasive cancer during pregnancy or women who were pregnant while receiving invasive cancer treatment between 1996 and 2021 were selected from the INCIP database. Descriptive statistics on oncological diagnosis, stage, antenatal treatment, obstetric and neonatal outcomes, and reported complications was performed. Proportions of events were estimated per 5-year time period with 95% confidence intervals using logistic regression models. A logistic regression model was used to explore the relationship between cancer stage and type, antenatal treatment and obstetric outcome [preterm premature rupture of membranes (PPROM), (planned or spontaneous) preterm delivery, small for gestational age (SGA), other obstetric or medical complications, admission in the neonatal intensive care unit (NICU)], pregnancy loss (miscarriages and stillbirths) and maternal death. Multiple imputation was used to deal with missing data.

**Results** In the pregnant cancer population (n=2174), preterm delivery (47%), delivery by cesarean section (45%), planned delivery (65%), SGA (27%), maternal death (2%) and NICU admission (33%) are common. Over time, more women

received antenatal chemotherapy ( $p < 0.001$ ), associated with an increase in SGA ( $p = 0.07$ ), spontaneous preterm delivery ( $p = 0.009$ ) and medical complications ( $p = 0.002$ ), and a decrease in elective preterm delivery ( $p < 0.001$ ), NICU admission ( $p = 0.044$ ) and neonatal complications ( $p < 0.001$ ). Most important prognostic factors for adverse outcomes were hematological cancers [maternal death OR 8.0, 95%CI (2.7–23.5),  $p < 0.001$ ], metastatic disease [maternal death OR 7.0, 95%CI (3.7–13.4),  $p < 0.001$ , pregnancy loss OR 2.2, 95%CI (1.5–3.2),  $p < 0.001$ ] and antenatal chemotherapy [PPROM OR 2.6, 95%CI (1.9–3.5),  $p < 0.001$ , SGA OR 1.6, 95%CI (1.3–2.1),  $p < 0.001$ , other obstetric complications OR 1.6, 95%CI (1.2–2.2),  $p = 0.003$ ]. **Conclusion** Antenatal chemotherapy will put a pregnancy at risk of complications and pregnant cancer patients should be managed in high risk obstetric units.

### 2022-RA-635-ESGO EVALUATION OF SERUM HE4 AND CA125 LEVELS IN THE EARLY POSTPARTUM PERIOD

<sup>1</sup>Ratko Delić, <sup>2</sup>Mario Štefanović, <sup>3</sup>Štefka Krivec, <sup>1</sup>Jakob Koren. <sup>1</sup>Department of Gynecology and Obstetrics, General and Teaching Hospital Celje, Celje, Slovenia; <sup>2</sup>Department of Clinical Chemistry, Sestre milosrdnice University Hospital Center, Zagreb, Croatia; <sup>3</sup>Department of Laboratory Medicine, General and Teaching Hospital Celje, Celje, Slovenia

10.1136/ijgc-2022-ESGO.371

**Introduction/Background** This study was conducted to analyze CA125 and HE4 levels in the early postpartum period

**Methodology** In a prospective study (OB/GYN Department, General Hospital, Celje, Slovenia) 277 women who were in the 1st-3rd day of postpartum period were included in the study. Biomarkers were analyzed with regard to each day of postpartum period (1st, 2nd and 3rd day after delivery) as well as regarding the method of delivery (vaginal delivery, elective and emergency cesarean section). CA 125 and HE4 were evaluated in consideration of their reference intervals,  $\leq 35$  IU/ml and  $\leq 140$  pmol/l (Elecys CA 125 II<sup>®</sup> assay and Elecsys HE4<sup>®</sup> assay, Roche Diagnostics Ltd.).

**Results** Biomarkers levels with regard to method of delivery. Women in the vaginal delivery group had significantly higher levels of CA125 than the women in both cesarean section groups (vaginal delivery group, n=144, median=36.9 IU/ml, elective cesarean, n=82, median=28.6 IU/ml and emergency cesarean, n=44, median=26.1 IU/ml,  $p < .001$ ). All HE4 measurements were within reference range; women in both cesarean section groups had significantly higher levels of HE4 than the women in the vaginal delivery group (elective cesarean, n=86, median=61.0 pmol/l, emergency cesarean, n=44, median=58.0 pmol/l and vaginal delivery group, n=147, median=54.0,  $p < .001$ ). **Biomarkers levels with regard to each day of postpartum period.** A significant number of women had high levels of CA125 ( $>100$  IU/mL), with a gradual decline during the first three postpartum days. However, there was not a statistically significant difference between groups. Again, all HE4 measurements were within reference range with a statistically significant decline during the second and third day after delivery (1st postpartum day, n=203, median=60.0 pmol/l vs 2nd, n=49, median=51.0 pmol/l and 3rd day, n=25, median=51.0 pmol/l,  $p < .001$ ).

**Conclusion** HE4 is more reliable marker of malignancy during the early postpartum period than CA125.